文献速递病毒性肝炎

联合HBV RNA与HBcrAg指导HBeAg阳性慢乙肝安全停用核苷(酸)类似物

Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
PubMed 文献 · J Infect Dis · 2020-01-01

多中心前瞻性试验纳入127例HBeAg阳性慢乙肝患者,停用替比夫定后随访4年。治疗结束时HBV RNA阴性且HBcrAg<4 log10 U/mL者无临床复发,而双阳性者复发率46.8%(P<.001);验证队列对应为0%和69.4%。低风险组HBsAg清除率更高(16.1% vs 1.3%,P=.002)。

要点

  • EOT时HBV RNA阴性且HBcrAg<4 log10 U/mL可预测停药后无临床复发。
  • 双阳性患者4年临床复发风险高,验证队列达69.4%。
  • 低风险组HBsAg清除率显著高于其他患者(16.1% vs 1.3%)。

核心结论

  • 联合HBV RNA与HBcrAg能满意预测HBeAg阳性非肝硬化慢乙肝患者停用核苷(酸)类似物后的临床复发和HBsAg清除。

研究设计与样本

  • 评估队列为多中心前瞻性试验中127例HBeAg阳性患者,达成HBeAg血清学转换且HBV DNA<50 IU/mL超过48周后停用替比夫定为基础的治疗。
  • 验证队列为59例停药前接受恩替卡韦或替诺福韦治疗的患者。

主要发现

  • 治疗结束时HBV RNA和HBcrAg是临床复发风险的显著独立预测因素。
  • 评估队列中,EOT时HBV RNA阴性且HBcrAg<4 log10 U/mL者(低风险组)无临床复发,而HBV RNA阳性且HBcrAg≥4 log10 U/mL者(高风险组)4年随访临床复发率为46.8%(P<.001)。
  • 验证队列中低风险组和高风险组的临床复发率分别为0%和69.4%(P<.001)。
  • 低风险组停药后HBsAg清除率高于其他患者(16.1% vs 1.3%,P=.002)。

关键数值与推荐

  • 低风险组定义:EOT时HBV RNA阴性且HBcrAg<4 log10 U/mL。
  • 高风险组定义:EOT时HBV RNA阳性且HBcrAg≥4 log10 U/mL。

临床怎么用

  • 对HBeAg阳性非肝硬化慢乙肝患者,停药前可检测HBV RNA和HBcrAg,双阴性且HBcrAg<4 log10 U/mL者停药后临床复发风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safe nucleos(t)ide analogue discontinuation in chronic hepatitis B (CHB) is an unmet need. We aimed to investigate whether combining hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) could perform satisfactorily in predicting off-treatment outcomes. METHODS: The evaluation cohort included 127 hepatitis B e antigen (HBeAg)-positive patients from a multicenter prospective trial who stopped telbivudine-based therapy after achieving HBeAg seroconversion and HBV DNA < 50 IU/mL for > 48 weeks. As validation, 59 patients treated with entecavir or tenofovir before discontinuation were analyzed. RESULTS: At the end of treatment (EOT), HBV RNA and HBcrAg were significant independent predictors of the clinical relapse risk. In the evaluation cohort, no clinical relapse occurred among patients with negative HBV RNA and HBcrAg < 4 log10 U/mL at EOT (low-risk group), whereas 46.8% patients with positive HBV RNA and HBcrAg ≥ 4 log10 U/mL (high-risk group) experienced clinical relapse during 4-year posttreatment follow-up (P < .001); the corresponding incidences in the validation cohort were 0% and 69.4% (P < .001), respectively. More patients in the low-risk group achieved HBsAg loss than the other patients after treatment cessation (16.1% vs 1.3%, P = .002). CONCLUSIONS: Combining HBV RNA and HBcrAg performed satisfactorily in predicting clinical relapse and HBsAg loss after treatment cessation in HBeAg-positive patients with CHB.The combination of hepatitis B virus RNA and hepatitis B core-related antigen performed satisfactorily in predicting clinical relapse and hepatitis B surface antigen loss after stopping nucleos(t)ide analogue treatment among noncirrhotic hepatitis B e antigen-positive patients with chronic hepatitis B and could be used to guide safe discontinuation.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Fan R, Peng J, Xie Q, et al. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. J Infect Dis. 2020. PMID: 32211776. doi:10.1093/infdis/jiaa136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。